Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Caswell-Jin JL, Somerfield MR, Khan MA, Kimmick GG, Gupta S, Kenan K, Peswani N, Hershman DL, Ernst BJ, Harvey BE, Krings G, McAndrew NP, Riaz IB, Vaz-Luis I, Villarreal-Garza C, Oberoi JK, Sadiq MH, He H, Chitale R, Hassett MJ

Open source

DOI: 10.1200/jco-26-02034
Published: 2026 Aug 26
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-26-02034,
  title = {Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.},
  author = {Caswell-Jin JL and Somerfield MR and Khan MA and Kimmick GG and Gupta S and Kenan K and Peswani N and Hershman DL and Ernst BJ and Harvey BE and Krings G and McAndrew NP and Riaz IB and Vaz-Luis I and Villarreal-Garza C and Oberoi JK and Sadiq MH and He H and Chitale R and Hassett MJ},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-26-02034},
  url = {https://doi.org/10.1200/jco-26-02034}
}

RIS

TY  - JOUR
TI  - Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.
AU  - Caswell-Jin JL
AU  - Somerfield MR
AU  - Khan MA
AU  - Kimmick GG
AU  - Gupta S
AU  - Kenan K
AU  - Peswani N
AU  - Hershman DL
AU  - Ernst BJ
AU  - Harvey BE
AU  - Krings G
AU  - McAndrew NP
AU  - Riaz IB
AU  - Vaz-Luis I
AU  - Villarreal-Garza C
AU  - Oberoi JK
AU  - Sadiq MH
AU  - He H
AU  - Chitale R
AU  - Hassett MJ
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-26-02034
UR  - https://doi.org/10.1200/jco-26-02034
ER  -

APA

JL, C., MR, S., MA, K., GG, K., S, G., K, K., N, P., DL, H., BJ, E., BE, H., G, K., NP, M., IB, R., I, V., C, V., JK, O., MH, S., H, H., R, C., & MJ, H. (2026). Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-26-02034

Source records

pubmed · retrieved 2026-09-25T07:44:21.333Z